In this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management. 

This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC.

In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy.

In this episode of MedOncNow, Dr. Christopher Booth discusses how 3 years of a structured exercise program after adjuvant chemotherapy for resected colon cancer can improve survival. This is an affordable, accessible and evidence-based strategy that can be incorporated into practice tomorrow.

In this episode of MedOncNow, Dr. Kevin Jao discusses Amivantamab + Lazertinib in the first-line treatment of EGFR-mutated NSCLC and how it fits into the treatment landscape. This is timely, as Johnson & Johnson has a time-limited access program to Ami-Laz for EGFR-mutated NSCLC, as per the Mariposa Regimen. 

More information in episodes 2 and 3. 

Proudly partnering with Oncology Education for the 2025 season.

MedOncNow has been made possible by the generous unrestricted support of BMS, Eisai, Johnson and Jonhson, Merck, Pfizer and Roche Canada.

In this episode of MedOncNow, Dr. Christine Brezden-Masley explores the clinical impact of Zolbetuximab in gastric and GEJ cancers, covering patient selection, treatment integration, and implications for systemic therapy delivery.  

This is timely as ASTELLAS is funding both testing for Claudin 18.2 and access to Zolbetuximab for Gastric and GEJ cancers across Canada.

  🎧 Catch up on Part 1 for insights into Claudin 18.2 testing and its role in guiding therapy decisions.

In this episode of MedOncNow, Dr. Brandon Sheffield explores the role of Claudin 18.2 as a biomarker in gastroesophageal junction (GEJ) and gastric cancers. He discusses key considerations for testing and the evolving implications for biomarker-driven treatment in gastric cancer.

This conversation is especially timely as ASTELLAS is currently funding Claudin 18.2 testing as part of the Gastric Cancer Biomarker Workflow initiative.

Access to Zolbetuximab from ASTELLAS will follow in May 2025.

Dr. Brandon Meyers joins Dr. Kassam to discuss the use of Adjuvant Aspirin in the management of curatively resected Colorectal Cancer in patients harbouring alterations in the PI3 Kinase pathway.  

This is a potentially practice-changing implementation of an affordable and tolerable drug that is easily accessible to patients.

In episode 3 of MedOncNow, Dr. Parneet Cheema joins Dr. Kassam to discuss how to implement the multiple options available for treating resectable NSCLC. She will help us choose between CheckMate 816 and KEYNOTE-671 while also discussing CheckMate-77T, AEGEAN and IMpower010.

Practically Speaking: Mariposa-2. In this episode of MedOncNow, Dr. Barb Melosky joins Dr. Kassam to discuss the use of Amivantimab + Carboplatin + Pemetrexed in the second-line treatment of EGFR-positive non small cell lung cancer (NSCLC) progressing after Osimertinib.  

A timely discussion, given that Johnson & Johnson now has a compassionate access program for this regimen. 

Dr. Kassam is joined by Dr. Aly-Khan Lalani to discuss the use of Belzutifan in the management of previously treated clear cell renal cell carcinoma. With Belzutifan now available in clinic, listen today for important guidance.